Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Alzheimer’s Diagnostics a Medical Breakthrough Attained by Global WholeHealth Partners Corp. As a Leading Researcher, Believes an Alzheimer’s Test Will Save Lives

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

April 19, 2021

Global WholeHealth Partners Corp. (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease.

“This could simply be described as nothing short of a Medical Breakthrough in Alzheimer’s Disease Diagnostic Testing for us,” said Charles Strongo, CEO of Global WholeHealth Partners Corp.

Global WholeHealth Partners now has the means to identify and test for Alzheimer’s disease using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis.  This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here.

“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo

The number of Americans living with Alzheimer’s is growing — and growing fast. More than 6 million Americans of all ages have Alzheimer’s. An estimated 6.2 million Americans age 65 and older are living with Alzheimer’s dementia in 2021. Seventy-two percent are age 75 or older. Details here.

Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people… Common behavioral symptoms of Alzheimer’s include sleeplessness, wandering, agitation, anxiety, and aggression. The damage initially appears to take place in the hippocampus and the entorhinal cortex, parts of the brain essential in forming memories. Fact sheet here.

There are many causes of dementia, and Alzheimer’s disease is the most common by far in the United States and many other countries. Alzheimer’s disease can be suspected clinically, and certain brain scans can almost make the diagnosis a certainty.

https://www.brightfocus.org/alzheimers/article/what-dementia

“Early detection for Alzheimer’s disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo.

Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, “The Company’s goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.”

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine